SCHEMBL358889

SCHEMBL358889

CC(=O)c1c(C)noc1C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
LMNA P02545 1/20 0.47
BRD4 O60885 2/20 0.47
GAA P10253 3/20 0.45
ALOX15 P16050 3/20 0.44
GFER P55789 1/20 0.44
HSD17B10 Q99714 2/20 0.42
USP2 O75604 1/20 0.42
TSHR P16473 1/20 0.42
CASP1 P29466 1/20 0.42
CASP7 P55210 1/20 0.42
BRD2 P25440 1/20 0.42
CREBBP Q92793 1/20 0.42
KDM4E B2RXH2 2/20 0.41
ATM Q13315 1/20 0.41
MAPT P10636 1/20 0.41
AGTR1 P30556 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL263098 0.81 ALDH1A1 (0.47) ALDH1A1L3MBTL1LMNAGAAALOX15
SCHEMBL223413 0.81 GAA (0.49) ALDH1A1L3MBTL1LMNAGAAALOX15
Hydrochloric Acid SCHEMBL19119186 0.79 GAA (0.47) ALDH1A1L3MBTL1LMNAGAAALOX15
SCHEMBL3643406 0.79 ALDH1A1 (0.46) ALDH1A1L3MBTL1LMNAGAAALOX15
SCHEMBL193631 0.79 LMNA (0.50) ALDH1A1L3MBTL1LMNAGAAALOX15
SCHEMBL352276 0.79 GAA (0.53) ALDH1A1L3MBTL1LMNAGAAALOX15
Hydrochloric Acid SCHEMBL5009791 0.77 GAA (0.51) ALDH1A1L3MBTL1LMNAGAAALOX15
SCHEMBL27554843 0.77 ALDH1A1 (0.39) ALDH1A1L3MBTL1LMNABRD4GAA
SCHEMBL2176508 0.77 ALDH1A1 (0.45) ALDH1A1L3MBTL1LMNAGAAALOX15
SCHEMBL14790745 0.77 ALDH1A1 (0.37) ALDH1A1L3MBTL1LMNABRD4GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022109001-A1 GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC (US) 2022-05-27 WO disclosed
EP-2935256-B1 4,6-DIARYLAMINOTHIAZINES AS BACE1 INHIBITORS AND THEIR USE FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION BRISTOL MYERS SQUIBB CO (US) 2018-01-24 EP disclosed
WO-2016202898-A1 GLUCOSE TRANSPORT INHIBITORS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-12-22 WO disclosed
US-9475784-B2 4,6-diarylaminothiazines as BACE1 inhibitors and their use for the reduction of beta-amyloid production BRISTOL-MYERS SQUIBB COMPANY (US) 2016-10-25 US disclosed
US-9475784-B2 4,6-diarylaminothiazines as BACE1 inhibitors and their use for the reduction of beta-amyloid production BRISTOL-MYERS SQUIBB COMPANY (US) 2016-10-25 US disclosed
US-9321790-B2 Pyrimidinone derivatives as antimalarial agents SANOFI (FR) 2016-04-26 US disclosed
US-9321790-B2 Pyrimidinone derivatives as antimalarial agents SANOFI (FR) 2016-04-26 US disclosed
WO-2016012333-A1 PESTICIDAL COMPOUNDS SYNGENTA PARTICIPATIONS AG (CH) 2016-01-28 WO disclosed
US-20150368213-A1 Novel Inhibitors of System Xc- THE UNIVERSITY OF MONTANA 2015-12-24 US disclosed
US-20150329506-A1 4,6-DIARYLAMINOTHIAZINES AS BACE1 INHIBITORS AND THEIR USE FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION BRISTOL-MYERS SQUIBB COMPANY (US) 2015-11-19 US disclosed
US-4814348-A ANTIULCER, ANTISECRETORY ROUSSEL UCLAF (FR) 1989-03-21 US disclosed
US-4694019-A ANTISECRETORY, ANTIULCER AGENTS ROUSSEL UCLAF (FR) 1987-09-15 US disclosed
US-4536499-A Isoxazolyl indolamines having anti-diabetic activity SANDOZ, INC. (US) 1985-08-20 US disclosed
US-4499279-A ANTIDIABETIC AND HYPOGLYCEMIC AGENTS SANDOZ, INC. (US) 1985-02-12 US disclosed
US-4467096-A ANTIDIABETIC AGENTS, INTERMEDIATES THEREFOR SANDOZ, INC. (US) 1984-08-21 US disclosed
US-4421752-A ANTIDIABETIC AGENT SANDOZ, INC. (US) 1983-12-20 US disclosed
US-4419353-A ANTIDIABETIC AGENTS SANDOZ, INC. (US) 1983-12-06 US disclosed
US-4397850-A HYPOGLYCEMIC, ANTIDIABETIC SANDOZ, INC. (US) 1983-08-09 US disclosed
US-4336391-A ANTIDIABETIC AGENTS SANDOZ, INC. (US) 1982-06-22 US disclosed
US-4336379-A ANTIDIABETIC AGENTS SANDOZ, INC. (US) 1982-06-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150368213-A1 Novel Inhibitors of System Xc- SLC7A11, SLC1A1, SLC1A2 ALDH1A1 1920/4885L3MBTL1 2965/4885LMNA 4865/4885
US-20150329506-A1 4,6-DIARYLAMINOTHIAZINES AS BACE1 INHIBITORS AND THEIR USE FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION BACE1, APP, BACE2 ALDH1A1 860/4885L3MBTL1 613/4885LMNA 493/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.